The upcoming San Antonio Breast Cancer Symposium on December 9 –13 might bring two new potential treatments for breast cancer. Swiss drugmaker Roche and U.S. group Merck & Co are going to present data about their drugs to treat triple negative breast cancer (TNBC), which does not respond to either the hormonal therapy or to the drugs that target HER2 receptors. Roche’s investigational drug, MPDL3280A, has not been approved for any type of cancer yet while Merck’s product, Keytruda, has been approved for treating melanoma last month in the United States. Both medications are immunotherapy drugs that work by blocking a protein known as Programmed Death receptor (PD-1), or a related target PD-L1. Considering October is the breast cancer awareness month, what are your thoughts or concerns regarding these new therapies?
For more information, please visit Reuters.
Image courtesy of [scottchan] / FreeDigitalPhotos.net